Vera Therapeutics, Inc. (VERA)
Data as of , from SEC Form 4 filings.
See up to 3 months of VERA. The 7-day demo opens the 1M and 3M ranges and puts VERA on your watchlist.
Start 7-day demoLatest VERA insider trades
About Vera Therapeutics, Inc. (VERA)
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
- BRISBANE, CA
- 361
- 2021
- XNAS
VERA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 4 | 55,500 | $2.04M |
| Grant or award | 2 | 107,998 | |
| Option exercise | 8 | 121,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
VERA insider transactions (Form 4)
5152 Form 4 filings on record, the earliest from Oct 11, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Marshall Fordyce - Officer | Option exercise | Class A Common Stock | 18,500 | $2.90 | $54K | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 18,500 | $37.00 | $685K | |
| Marshall Fordyce - Officer | Option exercise | Stock Option (Right to Buy) | 18,500 | $0.00 | - | |
| Joseph R. Young - Officer | Option exercise | Class A Common Stock | 5,000 | $3.94 | $20K | |
| Joseph R. Young - Officer | Option exercise | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| Marshall Fordyce - Officer | Option exercise | Class A Common Stock | 18,500 | $2.90 | $54K | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 18,500 | $35.12 footnote F2 | $650K | |
| Marshall Fordyce - Officer | Option exercise | Stock Option (Right to Buy) | 18,500 | $0.00 | - | |
| ||||||
| Marshall Fordyce - Officer | Option exercise | Class A Common Stock | 18,500 | $2.90 | $54K | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 18,412 | $37.93 footnote F3 | $698K | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 88 | $38.43 | $3K | |
| Marshall Fordyce - Officer | Option exercise | Stock Option (Right to Buy) | 18,500 | $0.00 | - | |
| ||||||
| Nancy Lee Boman - Officer | Grant or award | Class A Common Stock | 44,987 footnote F1 | $0.00 | - | |
| Nancy Lee Boman - Officer | Grant or award | Stock Option (right to buy) | 63,011 | $0.00 | - | |
| ||||||
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 1,000 | $40.78 footnote F2 | $41K | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 32,550 | $42.07 footnote F3 | $1.37M | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 10,500 | $42.86 footnote F4 | $450K | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 2,200 | $43.59 footnote F5 | $96K | |
| ||||||
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 18,412 | $37.93 footnote F2 | $698K | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 88 | $38.43 | $3K | |
| ||||||
| Scott W. Morrison | Grant or award | Stock Option (right to buy) | 17,084 | $0.00 | - | |
 Andrew Cheng | Grant or award | Stock Option (right to buy) | 17,084 | $0.00 | - | |
| Beth C. Seidenberg | Grant or award | Stock Option (right to buy) | 17,084 | $0.00 | - | |
| Christy J. Oliger | Grant or award | Stock Option (right to buy) | 17,084 | $0.00 | - | |
| James R. Meyers | Grant or award | Stock Option (right to buy) | 17,084 | $0.00 | - | |
| Kimball Hall | Grant or award | Stock Option (right to buy) | 17,084 | $0.00 | - | |
| Michael Morrissey | Grant or award | Stock Option (right to buy) | 17,084 | $0.00 | - | |
| Patrick G. Enright | Grant or award | Stock Option (right to buy) | 17,084 | $0.00 | - | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 14,219 | $36.64 footnote F2 | $521K | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 4,281 | $37.09 footnote F3 | $159K | |
| ||||||
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 14,130 | $43.66 footnote F2 | $617K | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 7,921 | $44.58 footnote F4 | $353K | |
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 900 | $45.51 footnote F5 | $41K | |
| ||||||
 Jane Wright-Mitchell - Officer | Grant or award | Class A Common Stock | 42,403 footnote F1 | $0.00 | - | |
| Jane Wright-Mitchell - Officer | Grant or award | Stock Option (right to buy) | 56,850 | $0.00 | - | |
| ||||||
| Joseph R. Young - Officer | Option exercise | Class A Common Stock | 10,000 | $3.94 | $39K | |
| Joseph R. Young - Officer | Option exercise | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Christopher Hite | Grant or award | Stock Option (right to buy) | 24,937 | $0.00 | - | |
| Robert Brenner - Officer | Open-market sale | Class A Common Stock | 2,151 | $41.98 footnote F3 | $90K | |
| ||||||
| Joseph R. Young - Officer | Open-market sale | Class A Common Stock | 3,117 | $41.98 footnote F3 | $131K | |
| ||||||
| Sean Grant - Officer | Open-market sale | Class A Common Stock | 4,949 | $41.98 footnote F3 | $208K | |
| ||||||
| Marshall Fordyce - Officer | Open-market sale | Class A Common Stock | 16,925 | $41.98 footnote F3 | $711K | |
| ||||||
| David Lee Johnson - Officer | Open-market sale | Class A Common Stock | 2,579 | $41.98 footnote F3 | $108K | |
| ||||||
| William D. Turner - Officer | Open-market sale | Class A Common Stock | 2,187 | $41.98 footnote F3 | $92K | |
| ||||||
| Laurence Matthew Skelton - Officer | Open-market sale | Class A Common Stock | 1,582 | $41.98 footnote F3 | $66K | |
| ||||||
| Joseph R. Young - Officer | Grant or award | Class A Common Stock | 10,000 footnote F1 | $0.00 | - | |
| Joseph R. Young - Officer | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| ||||||
| Marshall Fordyce - Officer | Grant or award | Class A Common Stock | 68,800 footnote F1 | $0.00 | - | |
| Marshall Fordyce - Officer | Grant or award | Stock Option (right to buy) | 137,500 | $0.00 | - | |
| ||||||
| Sean Grant - Officer | Grant or award | Class A Common Stock | 25,000 footnote F1 | $0.00 | - | |
| Sean Grant - Officer | Grant or award | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| ||||||
Item 7.01, 8.01, 9.01
Item 2.02, 9.01
Item 5.02
Item 8.01
Recent VERA Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| MARSHALL FORDYCE | Director, Officer | 64,750 | $2.22M | View on EDGAR | |
| - | - | - | - |
VERA insider trading FAQ
What is the latest insider trade for VERA?
Vera Therapeutics, Inc. (VERA) had 5 insider filings in the last 90 days, with the most recent on 2026-09-17. The full record for VERA runs to 52 Form 4 filings, the earliest from 2024-10-11. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying VERA stock?
No insider purchases of VERA were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling VERA stock?
4 insider sales of VERA were filed in the last 90 days, totaling $2.04M.
Where can I see VERA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects VERA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Marshall Fordyce view on EDGAR
- - Joseph R. Young view on EDGAR
- - Marshall Fordyce view on EDGAR
- - Marshall Fordyce view on EDGAR
- - Nancy Lee Boman view on EDGAR
- - Marshall Fordyce view on EDGAR
- - Marshall Fordyce view on EDGAR
- - Scott W. Morrison view on EDGAR
- - Andrew Cheng view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where VERA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow VERA with a 7-day demo
- VERA on your watchlist
- Every VERA Form 4 filing on record
- Up to 3 months of VERA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
